Page last updated: 2024-08-21

pyrazines and belinostat

pyrazines has been researched along with belinostat in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C1
Anderson, G; Belani, C; Feng, R; Lentzsch, S; Mapara, MY; Oton, A1
Chen, S; Dai, Y; Dent, P; Funk, VL; Grant, S; Kramer, LB1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, J1
Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Wang, L1
Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ1
Afqir, S; Belbaraka, R; Benjaafar, N; Elmajjaoui, S; Errihani, H; Ismaili, N; Tahri, A1

Trials

1 trial(s) available for pyrazines and belinostat

ArticleYear
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    British journal of haematology, 2011, Volume: 153, Issue:2

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Female; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; I-kappa B Kinase; Jurkat Cells; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrazines; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tubulin; U937 Cells; X-Linked Inhibitor of Apoptosis Protein

2011

Other Studies

6 other study(ies) available for pyrazines and belinostat

ArticleYear
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays

2007
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    British journal of haematology, 2007, Volume: 139, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; Osteogenesis; Oxidative Stress; Proto-Oncogene Proteins; Pyrazines; Reactive Oxygen Species; Sulfonamides

2007
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-15, Volume: 14, Issue:2

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Sulfonamides

2008
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-15, Volume: 16, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; Mice; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays

2010
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides

2011
[Urological cancers: ECCO/ESMO congress 2011].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:12 Pt 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Medical Oncology; Pyrazines; Societies, Medical; Sulfonamides; Sweden; Urologic Neoplasms

2012